Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.
McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG. McLornan DP, et al. Among authors: coyle vm. Clin Cancer Res. 2010 Jul 1;16(13):3442-51. doi: 10.1158/1078-0432.CCR-10-0052. Epub 2010 Jun 22. Clin Cancer Res. 2010. PMID: 20570920 Free PMC article.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R. Jamieson D, et al. Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28. Eur J Cancer. 2016. PMID: 27693888 Free article. Clinical Trial.
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR. Woodcock VK, et al. Among authors: coyle vm. Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13. Br J Cancer. 2018. PMID: 29438361 Free PMC article. Clinical Trial.
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Forde C, McMullan R, Clarke M, Wilson RH, Plummer R, Grayson M, McDowell C, Agus A, Doran A, McAuley DF, Thomas AL, Barnes RA, Adams R, Chau I, Coyle V. Forde C, et al. Trials. 2020 May 27;21(1):431. doi: 10.1186/s13063-020-04241-1. Trials. 2020. PMID: 32460818 Free PMC article.
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
El Helali A, Plummer R, Jayson GC, Coyle VM, Drew Y, Mescallado N, Harris N, Clamp AR, McCann J, Swaisland H, Kennedy RD, Cranston AN, Wilson RH. El Helali A, et al. Among authors: coyle vm. Br J Cancer. 2022 Jul;127(1):92-101. doi: 10.1038/s41416-022-01780-z. Epub 2022 May 14. Br J Cancer. 2022. PMID: 35568736 Free PMC article.
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
Coyle V, Forde C, Adams R, Agus A, Barnes R, Chau I, Clarke M, Doran A, Grayson M, McAuley D, McDowell C, Phair G, Plummer R, Storey D, Thomas A, Wilson R, McMullan R. Coyle V, et al. Health Technol Assess. 2024 Mar;28(14):1-101. doi: 10.3310/RGTP7112. Health Technol Assess. 2024. PMID: 38512064 Free PMC article. Clinical Trial.
35 results